What's already known about this topic?

  • Noninvasive DNA testing (NIDT) is recommended in many developed countries as an option for pregnant women who have already been determined to be at high risk for fetal aneuploidy.
  • Over 2 years of clinical experience has been accumulated with offering NIDT as an advanced screen for fetal autosomal aneuploidy.
  • At the present time, most testing is being performed by commercial organizations.

What does this study add?

  • This study provides a written transcript to accompany an oral debate that was presented at the 17th International Conference on Prenatal Diagnosis and Therapy in Lisbon, Portugal, on 3 June 2013.
  • The debaters, who are both experts in maternal–fetal medicine, consider the benefits and limitations of offering NIDT to all pregnant women regardless of their a priori risk of having a fetus with a chromosome abnormality.